Omentin-1 vs Mazdutide
Head-to-head comparison of Omentin-1 (Omentin-1 (Intelectin-1, ITLN1)) and Mazdutide (IBI362, long-acting GLP-1 receptor and glucagon receptor dual agonist) — benefits, dosing, side effects, research data, and where to buy.
| Property | Omentin-1 | Mazdutide |
|---|---|---|
| Category | Diabetes & Metabolic | Weight Management |
| Full Name | Omentin-1 (Intelectin-1, ITLN1) | IBI362, long-acting GLP-1 receptor and glucagon receptor dual agonist |
| Molecular Weight | ~35 kDa | ~5,000 Da |
| Half-Life | hours | 5-7 days |
| Amino Acids | 313 | 37 |
| Typical Dose | No approved human dose; research use only | 1-6 mg weekly in obesity trials |
| Route | IV|SC | Subcutaneous |
| Purity | ≥98% | ≥98% |
| Studies Count | 82 | 28 |
| Research Status | Pre-clinical | Clinical |
Omentin-1 Benefits
- ✓insulin sensitivity
- ✓glucose uptake
- ✓lipid handling
Mazdutide Benefits
- ✓clinically meaningful weight loss
- ✓better glycemic control
- ✓reduced waist circumference
- ✓improved lipid profile
Omentin-1 Dosing
not established|not established
Mazdutide Dosing
Once-weekly SC titration|Dose escalation every 4 weeks|Use with lifestyle modification
Omentin-1 Side Effects
- ⚠unknown
- ⚠immunogenicity risk
Mazdutide Side Effects
- ⚠nausea
- ⚠vomiting
- ⚠constipation
Research Overview
Omentin-1
Lower omentin-1 levels are often associated with obesity, insulin resistance, and metabolic syndrome. Research continues on its use as a biomarker and as a mechanistic lead for AMPK-linked metabolic interventions.
Mazdutide
Clinical programs have shown substantial reductions in body weight and improvements in cardiometabolic risk markers. It is a prominent newer dual agonist in the obesity literature.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.